{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:17:36Z","timestamp":1791145056189,"version":"4.1.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The identification of JAK2\/MPL mutations in patients with myeloproliferative neoplasms (MPN) has led to the clinical development of JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms in myelofibrosis and improves overall survival; however, the mechanism by which JAK inhibitors achieve efficacy has not been delineated. Patients with MPN present with increased levels of circulating proinflammatory cytokines, which are mitigated by JAK inhibitor therapy. We sought to elucidate mechanisms by which JAK inhibitors attenuate cytokine-mediated pathophysiology. Single-cell profiling demonstrated that hematopoietic cells from myelofibrosis models and patient samples aberrantly secrete inflammatory cytokines. Pan-hematopoietic Stat3 deletion reduced disease severity and attenuated cytokine secretion, with similar efficacy as observed with ruxolitinib therapy. In contrast, Stat3 deletion restricted to MPN cells did not reduce disease severity or cytokine production. Consistent with these observations, we found that malignant and nonmalignant cells aberrantly secrete cytokines and JAK inhibition reduces cytokine production from both populations.<\/jats:p>\n                  <jats:p>Significance: Our results demonstrate that JAK\u2013STAT3-mediated cytokine production from malignant and nonmalignant cells contributes to MPN pathogenesis and that JAK inhibition in both populations is required for therapeutic efficacy. These findings provide novel insight into the mechanisms by which JAK kinase inhibition achieves therapeutic efficacy in MPNs. Cancer Discov; 5(3); 316\u201331. \u00a92015 AACR.<\/jats:p>\n                  <jats:p>See related commentary by Belver and Ferrando, p. 234<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 213<\/jats:p>","DOI":"10.1158\/2159-8290.cd-14-0736","type":"journal-article","created":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T00:52:55Z","timestamp":1420764775000},"page":"316-331","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":307,"title":["JAK\u2013STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response"],"prefix":"10.1158","volume":"5","author":[{"given":"Maria","family":"Kleppe","sequence":"first","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsuk","family":"Kwak","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Engineering, Yale University, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Koppikar","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Riester","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"4Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Keller","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Bastian","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Hricik","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Bhagwat","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"5Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Sophia","family":"McKenney","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"5Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, New York."},{"name":"6Weill Cornell\/Rockefeller\/Sloan Kettering Tri-Institutional MD\u2013PhD Program, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymia","family":"Papalexi","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"7Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"7Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachie","family":"Marubayashi","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Chen","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Engineering, Yale University, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Romanet","sequence":"additional","affiliation":[{"name":"8Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan S.","family":"Fridman","sequence":"additional","affiliation":[{"name":"9Incyte Corporation, Wilmington, Delaware."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Bromberg","sequence":"additional","affiliation":[{"name":"10Breast Cancer Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Teruya-Feldstein","sequence":"additional","affiliation":[{"name":"11Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Murakami","sequence":"additional","affiliation":[{"name":"8Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Radimerski","sequence":"additional","affiliation":[{"name":"8Disease Area Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Michor","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"4Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fan","sequence":"additional","affiliation":[{"name":"2Department of Biomedical Engineering, Yale University, New Haven, Connecticut."},{"name":"12Yale Comprehensive Cancer Center, New Haven, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[{"name":"1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"7Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2015,3,5]]},"reference":[{"key":"2022060623582126900_bib1","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"2022060623582126900_bib2","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"2022060623582126900_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","article-title":"Molecular aspects of myeloproliferative neoplasms","volume":"91","author":"Delhommeau","year":"2010","journal-title":"Int J Hematol"},{"key":"2022060623582126900_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2022060623582126900_bib5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060623582126900_bib6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2022060623582126900_bib7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2022060623582126900_bib8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060623582126900_bib9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"2022060623582126900_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1582-4934.2008.00559.x","article-title":"Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1","volume":"13","author":"Tefferi","year":"2009","journal-title":"J Cell Mol Med"},{"key":"2022060623582126900_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond","volume":"10","author":"Quintas-Cardama","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2022060623582126900_bib12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022060623582126900_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060623582126900_bib14","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"2022060623582126900_bib15","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"2022060623582126900_bib16","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1021\/ac400082e","article-title":"High-throughput secretomic analysis of single cells to assess functional cellular heterogeneity","volume":"85","author":"Lu","year":"2013","journal-title":"Anal Chem"},{"key":"2022060623582126900_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm.2375","article-title":"A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells","volume":"17","author":"Ma","year":"2011","journal-title":"Nat Med"},{"key":"2022060623582126900_bib18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/nbt.1507","article-title":"Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood","volume":"26","author":"Fan","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2022060623582126900_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.stem.2013.06.009","article-title":"Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche","volume":"13","author":"Schepers","year":"2013","journal-title":"Cell Stem Cell"},{"key":"2022060623582126900_bib20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022060623582126900_bib21","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"key":"2022060623582126900_bib22","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"2022060623582126900_bib23","first-page":"415","article-title":"New pieces of a puzzle: the current biological picture of MPN","volume":"1826","author":"Kleppe","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2022060623582126900_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature"},{"key":"2022060623582126900_bib25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"2022060623582126900_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.stem.2014.06.020","article-title":"Acute myelogenous leukemia-induced sympathetic neuropathy promotes malignancy in an altered hematopoietic stem cell niche","volume":"15","author":"Hanoun","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2022060623582126900_bib27","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"2022060623582126900_bib28","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.4049\/jimmunol.161.9.4652","article-title":"Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice","volume":"161","author":"Takeda","year":"1998","journal-title":"J Immunol"},{"key":"2022060623582126900_bib29","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes","volume":"111","author":"Wernig","year":"2008","journal-title":"Blood"},{"key":"2022060623582126900_bib30","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","article-title":"Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis","volume":"115","author":"Koppikar","year":"2010","journal-title":"Blood"},{"key":"2022060623582126900_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1126\/science.288.5463.113","article-title":"Monolithic microfabricated valves and pumps by multilayer soft lithography","volume":"288","author":"Unger","year":"2000","journal-title":"Science"},{"key":"2022060623582126900_bib32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nbt.2317","article-title":"Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators","volume":"30","author":"Bodenmiller","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2022060623582126900_bib33","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nbt.1991","article-title":"Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE","volume":"29","author":"Qiu","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2022060623582126900_bib34","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.stem.2014.01.007","article-title":"Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis","volume":"14","author":"Zhao","year":"2014","journal-title":"Cell Stem Cell"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/5\/3\/316\/1836734\/316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/5\/3\/316\/1836734\/316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T14:19:44Z","timestamp":1690813184000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/5\/3\/316\/4732\/JAK-STAT-Pathway-Activation-in-Malignant-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,1]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,5]]},"published-print":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-14-0736","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725309550.793516231","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6546231.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530627","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22530627.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6546231","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,1]]}}}